ARB, ACEi, DRi Effects on COVID-19 Course Disease (BIRCOV)

Medical Practice Prof D. Ivanov

Status: Completed

Conditions: COVID-19; Hypertension

Treatments: Drug: Direct renin inhibitor; Drug: Angiotensin converting enzyme inhibitor; Drug: Angiotensin Receptor Blockers

Study type: Observational

Funder types: Other

Identifiers

NCT04364984

COVID20

Details and patient eligibility

About

It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.

Full description

POEM (Patient-Oriented Evidence that Matters) intervention is performed as an open prospective randomized two medical centres trial in subjects suffering from COVID-19 who have been receiving iRAS, either ACEi, ARB or DRi as basic antihypertensive therapy.

COVID-19 is confirmed by a PCR test, the disease follow-up is divided into 2 periods: up to 12 weeks and up to 24 weeks.

Primary Outcome Measure: BP was known one week before COVID-19 and is tested during the disease onset on weeks 2, 4, 12, 24. Secondary Outcome Measures are clinical features. Subanalysis in patients with CKD is additionally performed for those who have CKD.

Enrollment: 112 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypertensive person, stage 1-2

Exclusion criteria

• Hypertensive subjects, stage 3, HF (NYHA) 3-4

Trial design

112 participants in 3 patient groups

ARB group

Description:

Hypertensive patients with COVID-19 who received ARBs

Treatment:

Drug: Angiotensin Receptor Blockers

ACEi group

Description:

Hypertensive patients with COVID-19 who received ACEis

Treatment:

Drug: Angiotensin converting enzyme inhibitor

DRi group

Description:

Hypertensive patients with COVID-19 who received direct renin inhibitor (DRis)

Treatment:

Drug: Direct renin inhibitor